公开(公告)号：US20240315974A1

公开(公告)日：2024-09-26

申请号：US18736621

申请日：2024-06-07

Applicant: MATRIPHARM INTERNATIONAL INC.

Inventor： Tien Canh LE ,  Mircea-Alexandru MATEESCU

IPC: A61K9/20 ,  A61K31/192 ,  A61K31/405 ,  A61K31/616 ,  A61K45/06

CPC classification number: A61K9/2059 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/205 ,  A61K9/2054 ,  A61K31/192 ,  A61K31/405 ,  A61K31/616 ,  A61K45/06

Abstract: The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.

公开(公告)号：US20240315968A1

公开(公告)日：2024-09-26

申请号：US18615846

申请日：2024-03-25

Applicant: inSitu Biologics, Inc.

Inventor： William J. Taylor ,  Kelsey Pflepsen

IPC: A61K9/107 ,  A61K9/00 ,  A61K31/337 ,  A61K31/704 ,  A61K45/06 ,  A61K47/10 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44

CPC classification number: A61K9/107 ,  A61K9/0019 ,  A61K31/337 ,  A61K31/704 ,  A61K45/06 ,  A61K47/10 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44

Abstract: Disclosed herein is composition for treating a tumor in a subject in need thereof that comprises an emulsion comprising: an aqueous carrier; and liquid lipid phase dispersed into droplets within the aqueous carrier, and a first chemotherapeutic agent within the lipid phase. In certain embodiments, the first chemotherapeutic agent comprises a first plurality of chemotherapeutic agent crystals. In certain alternative embodiments, the first chemotherapeutic agent is dissolved with the lipid phase. In certain implementations, the composition further comprises a second plurality of chemotherapeutic agent crystals within the aqueous carrier, but not the lipid phase and wherein the second plurality of chemotherapeutic agent crystals dissolves and elutes from the emulsion at a faster rate than the first plurality chemotherapeutic agent crystals. In certain implementations, the composition further comprises one or more additional chemotherapeutic agents, different from the first chemotherapeutic agent.

公开(公告)号：US12098195B2

公开(公告)日：2024-09-24

申请号：US17253207

申请日：2019-11-27

Applicant: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.

Inventor： Junjian Liu ,  Min Wu ,  Li Li ,  Shuaixiang Zhou ,  Enkun Zhou

IPC: C07K16/24 ,  A61K39/395 ,  A61K47/68 ,  A61P37/06 ,  G01N33/564 ,  A61K39/00 ,  A61K45/06

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K47/6845 ,  A61P37/06 ,  G01N33/564 ,  A61K2039/505 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to a novel antibody and an antibody fragment thereof that specifically bind to IL-23p19 and a composition comprising the antibody or the antibody fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the present invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment.

公开(公告)号：US12097289B2

公开(公告)日：2024-09-24

申请号：US17135646

申请日：2020-12-28

Applicant: GLOBAL HEALTH SOLUTIONS LLC

Inventor： Bradley Burnam

IPC: A61K9/10 ,  A61K8/00 ,  A61K8/04 ,  A61K8/31 ,  A61K9/00 ,  A61K9/06 ,  A61K31/785 ,  A61K38/18 ,  A61K38/20 ,  A61K45/06 ,  A61K47/06 ,  A61Q19/00

CPC classification number: A61K9/10 ,  A61K8/00 ,  A61K8/044 ,  A61K8/31 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/785 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/20 ,  A61K45/06 ,  A61K47/06 ,  A61Q19/00 ,  A61K2800/10

Abstract: The disclosure provides stable formulations of cationic biocides that are primarily used in the treatment and prevention of infections. The disclosure is also concerned with processes for forming stable emulsions of cationic biocides and petrolatum.

公开(公告)号：US12097277B2

公开(公告)日：2024-09-24

申请号：US17252532

申请日：2019-06-14

Applicant: CROMA-PHARMA GMBH

Inventor： Martin Prinz ,  Ralph Hollaus ,  Robert Sachsenhofer

IPC: A61K31/728 ,  A61K8/04 ,  A61K8/73 ,  A61K45/06 ,  A61K47/06 ,  A61L27/20 ,  A61L27/52 ,  A61L31/04 ,  A61L31/14 ,  C08L5/08

CPC classification number: A61K8/735 ,  A61K8/042 ,  A61K31/728 ,  A61K45/06 ,  A61K47/06 ,  A61L27/20 ,  A61L27/52 ,  A61L31/042 ,  A61L31/145 ,  C08L5/08 ,  A61L2300/236 ,  A61L2300/402 ,  A61L2400/06 ,  A61L2430/34

Abstract: A sterile hydrogel composition comprising a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of a thiol-modified hyaluronan and wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of more than about 80 μmol per gram polymer, wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of less than about 280 μmol per gram polymer, wherein the composition has a residual thiol content of less than 20% in respect to the degree of modification of the thiol-modified hyaluronan.

公开(公告)号：US12097241B2

公开(公告)日：2024-09-24

申请号：US17573238

申请日：2022-01-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Gene M. Dubowchik ,  Olafur S. Gudmundsson ,  Xiaojun Han ,  R. Michael Lawrence ,  Dasa Lipovsek ,  Cort S. Madsen ,  Claudio Mapelli ,  Paul E. Morin ,  Michael C. Myers

IPC: A61K38/18 ,  A61K38/22 ,  C07K1/107 ,  C07K14/64 ,  A61K38/00 ,  A61K45/06 ,  A61K47/64 ,  A61P9/00

CPC classification number: A61K38/18 ,  A61K38/2221 ,  C07K1/1077 ,  C07K14/64 ,  A61K38/00 ,  A61K45/06 ,  A61K47/64 ,  A61P9/00

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

公开(公告)号：US12097222B2

公开(公告)日：2024-09-24

申请号：US16893306

申请日：2020-06-04

Applicant: Spiritus Therapeutics, Inc.

Inventor： Jodi Gurney ,  Robin Smith

IPC: A61K35/28 ,  A61K9/00 ,  A61K9/127 ,  A61K35/17 ,  A61K45/06 ,  A61P11/00 ,  C12N15/113

CPC classification number: A61K35/28 ,  A61K9/0073 ,  A61K9/127 ,  A61K35/17 ,  A61K45/06 ,  A61P11/00 ,  C12N15/113

Abstract: The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.

公开(公告)号：US12097172B2

公开(公告)日：2024-09-24

申请号：US17679842

申请日：2022-02-24

Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION ,  DOMPE FARMACEUTICI S.P.A.

Inventor： Paolo Fiorina ,  Roberto Bassi ,  Andrea Vergani ,  Marcello Allegretti

IPC: A61K31/18 ,  A61K31/426 ,  A61K45/06 ,  A61P3/10 ,  A61P13/12 ,  G01N33/68

CPC classification number: A61K31/18 ,  A61K31/426 ,  A61K45/06 ,  A61P3/10 ,  A61P13/12 ,  G01N33/68 ,  A61K31/18 ,  A61K2300/00

Abstract: Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.

公开(公告)号：US20240310266A1

公开(公告)日：2024-09-19

申请号：US18282414

申请日：2022-03-18

Applicant: Novartis AG

Inventor： Jan Brase ,  Bin Fu ,  James Garrett ,  Gullu Gorgun ,  Daniel Gusenleitner ,  Radha Ramesh ,  Alexander Savchenko

IPC: G01N15/10 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12Q1/6886 ,  G01N15/14 ,  G01N33/574

CPC classification number: G01N15/10 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  C12Q1/6886 ,  G01N33/57492 ,  C07K2317/565 ,  C12Q2600/106 ,  G01N2015/1006 ,  G01N2015/1486 ,  G01N2474/20

Abstract: The disclosure relates to the use of biomarkers for predicting the response to cancer (e.g., melanoma) treatments, for selecting a treatment for a cancer patient (e.g., using targeted therapy, e.g., using an agent targeting BRAF and/or an agent targeting MEK in combination with an immuno-oncology therapy (e.g., an anti-PD-1 therapy)), for stratifying cancer patients into different treatment groups, for treating cancer patients, and for predicting clinical outcome in cancer.

公开(公告)号：US20240309329A1

公开(公告)日：2024-09-19

申请号：US18607107

申请日：2024-03-15

Applicant: MAM Holdings of West Florida, L.L.C.

Inventor： Carl Randall Harrell

IPC: C12N5/0775 ,  A61K9/50 ,  A61K45/06

CPC classification number: C12N5/0662 ,  A61K9/5068 ,  A61K45/06 ,  C12N2500/02

Abstract: The present invention relates generally to methods and compositions for immunotherapy and drug delivery. In particular, the present invention relates to methods of producing exosomes from mesenchymal stem cells and, optionally, loading said exosomes with one or more bioactive substances. The exosomes may be loaded using electroporation with one or more bioactive substances such as proteins, miRNAs, and/or siRNA. In specific embodiments, the exosomes may be provided to an individual in need thereof, including where the individual in need thereof is an individual having a medical disorder such as cancer and other disorders.